Simpson Thacher represented the underwriters, led by BofA Securities, HSBC, Mizuho and Santander, in a U.S. registered public offering of $2.25 billion of senior notes with maturities ranging between five and ten years by AstraZeneca Finance LLC, a wholly-owned subsidiary of AstraZeneca PLC. The offering closed on March 3, 2023, with the net proceeds to be used for general corporate purposes, which may include the refinancing of existing indebtedness.
AstraZeneca is a global, science-led, patient-focused pharmaceutical business that focuses on the discovery, development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas: Oncology, BioPharmaceuticals (comprising Cardiovascular, Renal & Metabolism, Respiratory & Immunology and Vaccines & Immune Therapies) and Rare Disease.
The Simpson Thacher team included Mark Brod, Srishti Gupta and Amanda Obi (Capital Markets); Jonathan Cantor and Scott Grundei (Tax); Vanessa Burrows (Healthcare Regulatory); Bobbie Burrows, Alysha Sekhon and Mark Natividad (IP); and Jennie Getsin (FINRA and Blue Sky).